Research Programme: Lead 212 conjugated targeted therapies - Orano Med/Undisclosed company

Alternative Names: ²¹²Pb TAT - Orano Med/Undisclosed company

Latest Information Update: 17 Oct 2023

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Orano Med; Undisclosed Company
Class Antineoplastics; Drug conjugates; Lead radioisotopes; Radiopharmaceuticals
Mechanism of Action Ionising radiation emitters

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

17 Oct 2023 Research Programme: Lead 212 conjugated targeted therapies - Orano Med/Undisclosed company is available for licensing as of 17 Oct 2023. https://www.oranomed.com/en/pipeline (Orano Med pipeline, October 2023)
22 Aug 2023 Preclinical trials in Cancer in USA (unspecified route) (Orano Med pipeline, August 2023)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com